Vaccine pioneer BioNTech hires former Morphosys exec as finance chief By Reuters

<iframe src=”//″ width=”250″ height=”250″ scrolling=”no” border=”0″ marginwidth=”0″ style=”border:none;” frameborder=”0″></iframe>


© Reuters. FILE PHOTO: General view shows the laboratories of BioNTech at their COVID-19 vaccine production facility as the spread of the coronavirus disease (COVID-19) continues, in Marburg, Germany, March 27, 2021. REUTERS/Kai Pfaffenbach/File Photo


By Ludwig Burger

FRANKFURT (Reuters) – BioNTech, the Pfizer (NYSE:) partner that invented the Comirnaty COVID-19 vaccine, has appointed former Morphosys executive Jens Holstein as chief financial officer to help it grow into a global immunotherapy company.

Sierk Poetting, who is finance chief and chief operating officer, will focus on the latter role when Holstein joins in July, to further expand BioNTech’s global vaccine production network, it said in a statement on Tuesday.

BioNTech in December became the first Western company to win preliminary approval for its vaccine to prevent the life threatening disease caused by the novel coronavirus.

Holstein will oversee a massive inflow of cash that will potentially fuel the ambitions of BioNTech’s co-founder and Chief Executive Ugur Sahin to develop precision immunotherapies against various forms of cancer and other diseases.

Vaccine supply deals lined up for this year alone are worth 12.4 billion euros ($15.1 billion) in revenue for BioNTech, with more contracts on the cards.

Holstein quit as Morphosys CFO in December to pursue new challenges after almost 10 years there. During his tenure, Morphosys added a Nasdaq flotation to its listing in Germany and won approval for its first product, Tremfya against psoriasis.

Previously, Holstein served in various finance and management positions at diversified healthcare group Fresenius SE (DE:).

($1 = 0.8190 euros)

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Be the first to comment

Leave a Reply

Your email address will not be published.


17 + = 20